First Long Island Investors Boosts Eli Lilly Stake

Institutional investor increases holdings in pharmaceutical giant by over 50%

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

First Long Island Investors LLC, an institutional investor, has increased its stake in Eli Lilly and Company (NYSE: LLY) by 54.4% in the third quarter. The firm now owns 43,841 shares of the pharmaceutical company's stock, valued at $33.45 million as of its latest SEC filing.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for its innovative medicines and therapies. This increase in holdings by First Long Island Investors suggests the firm sees strong potential in Lilly's future performance and growth prospects.

The details

According to the 13F filing, First Long Island Investors purchased an additional 15,446 shares of Eli Lilly during the third quarter, bringing its total position to 43,841 shares. This represents approximately 2.5% of the firm's total investment portfolio.

  • First Long Island Investors increased its Eli Lilly holdings in the 3rd quarter of 2026.

The players

First Long Island Investors LLC

An institutional investment firm that manages assets for clients.

Eli Lilly and Company

A global pharmaceutical company that researches, develops, manufactures, and commercializes a broad range of medicines and therapies.

Got photos? Submit your photos here. ›

The takeaway

This increase in holdings by a major institutional investor underscores the confidence in Eli Lilly's long-term growth potential within the pharmaceutical industry. As Lilly continues to innovate and expand its product pipeline, investors like First Long Island are positioning themselves to potentially benefit from the company's future success.